Clinical Control Criteria to Determine Disease Control in Patients with Severe COPD: The CLAVE Study
Received 7 October 2020
Accepted for publication 7 January 2021
Published 25 January 2021 Volume 2021:16 Pages 137—146
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Richard Russell
Juan José Soler-Cataluña,1 Pere Almagro,2 Arturo Huerta,3 Diego González-Segura,4 Borja G Cosío5 On behalf of the CLAVE study Investigators
1Department of Pneumology, Hospital Universitari Arnau de Vilanova and CIBERES, Valencia, Spain; 2Multimorbidity Patients Unit. Internal Medicine Department, H. Mutua Terrassa University Hospital, Terrassa, Barcelona, Spain; 3Emergency Department – Medicine and Pulmonary Section, H. Clínic de Barcelona, Barcelona, Spain; 4Medical Department, Chiesi SAU, Barcelona, Spain; 5Department of Pneumology, H. Universitari Son Espases Hospital-IdISBa and CIBERES, Palma de Mallorca, Balearic Islands, Spain
Correspondence: Juan José Soler-Cataluña
Department of Pneumology, H. Universitari Arnau de Vilanova, C/San Clemente 12, Valencia 46015, Spain
Tel + 973 24 81 00
Background: Clinical control in chronic obstructive pulmonary disease (COPD) has not been completely characterized. A proposal of clinical control criteria (CCC) has been recently defined and validated as a tool for determining control, but there is scarce information on patients with severe COPD.
Objective: To evaluate clinical control in severe COPD using the CCC.
Patients and Methods: The study design was observational, multicenter, cross-sectional study involving 4801 patients with severe COPD in Spain. Clinical control was defined according to clinical impact (dyspnea grade, use of rescue treatment in last week, sputum color, and daily physical activity) and stability (exacerbations in last 3 months and patient’s perception about health status). Clinical control of COPD was alternatively evaluated with the COPD assessment test (CAT) and the presence of exacerbations in the last 3 months.
Results: According to CCC, 61.0% of patients had low clinical impact, and 41.4% showed clinical stability. Overall, 29.9% of patients had both low clinical impact and stability (controlled), whereas 70.1% showed high clinical impact and/or no clinical stability (non-controlled). COPD control was also assessed by using only the definition of CAT≤ 16 and no exacerbations in the last 3 months. Results obtained with this definition were similar to those obtained by CCC, and the concordance between both definitions was high (Kappa index = 0.698).
Conclusion: By using the CCC, approximately only one third of patients with severe COPD were considered as controlled. Physical activity, adherence to inhalers, age, post-bronchodilator FEV1, age-adjusted Charlson comorbidity index, and healthcare level were independent factors associated with COPD control.
Keywords: COPD, control, clinical, exacerbations, criteria, CAT
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]